<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="171241">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867217</url>
  </required_header>
  <id_info>
    <org_study_id>11548</org_study_id>
    <nct_id>NCT00867217</nct_id>
  </id_info>
  <brief_title>Vitamin D3 for Aromatase Inhibitor Induced Arthralgias</brief_title>
  <acronym>VITAL</acronym>
  <official_title>A Randomized Trial to Evaluate the Benefit of High Dose Vitamin D3 on Aromatase Inhibitor Letrozole-Associated Musculoskeletal Symptoms and Fatigue (The VITAL Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BTR Group</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose is to determine if high dose vitamin D3 reduces the incidence of
      musculoskeletal symptoms associated with the aromatase inhibitor letrozole in women with
      early stage breast cancer and low serum vitamin D levels. The primary hypothesis is that
      high dose vitamin D3 prevents the worsening of musculoskeletal symptoms when compared to a
      standard dose vitamin D3 treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will examine the relationship between vitamin D levels (25-hydroxyvitamin D)
      and various quality of life measures in women being treated with letrozole as standard care
      for early stage breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessments of musculoskeletal symptoms: Health Assessment Questionnaire II (HAQ II), Joint Pain Score, Brief Pain Inventory (BPI), Brief Fatigue Inventory (BFI)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog pain scale; hand grip strength; menopausal Quality of Life (MEN-QOL); serum 25OHD levels; serum letrozole levels; single nucleotide polymorphisms of vitamin D receptor genes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Vitamin D3 capsules given weekly along with standard of care medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given weekly along with standard of care medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Vitamin D3</intervention_name>
    <description>Drug: High Dose Vitamin D3 High Dose Vitamin D3 (3 capsules of 10,000 IU or placebo) weekly for 24 weeks Arms: Vitamin D</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>there are none</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo Placebo comparator Arms: Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>there are none</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women newly diagnosed with early stage breast cancer, who would be
             treated with an aromatase inhibitor

          -  Serum 25OHD levels &lt; 40 ng/ml

        Exclusion Criteria:

          -  Severe or debilitating musculoskeletal pain

          -  Known metastatic disease

          -  History of renal stones

          -  History of hypercalcemia or hyperthyroidism

          -  Currently receiving adjuvant or neoadjuvant chemotherapy

          -  Currently receiving other investigational agents
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qamar J Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Kansas, P.A.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>August 17, 2010</lastchanged_date>
  <firstreceived_date>March 20, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Qamar J. Khan, MD</name_title>
    <organization>University of Kansas Medical Center</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
